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Abstract
Backgrounds: Disseminated Penicillium marneffei infection is one of the most common HIV-related opportunistic
infections in Southeast Asia. Immune reconstitution inflammatory syndrome (IRIS) is a complication related to
antiretroviral therapy (ART)-induced immune restoration. The aim of this report is to present a case of HIV-infected
child who developed an unmasking type of IRIS caused by disseminated P. marneffei infection after ART initiation.
Case presentation: A 14-year-old Thai HIV-infected girl presented with high-grade fever, multiple painful ulcerated
oral lesions, generalized non-pruritic erythrematous skin papules and nodules with central umbilication, and
multiple swollen, warm, and tender joints 8 weeks after ART initiation. At that time, her CD4
+ cell count was 7.2%
or 39 cells/mm
3. On admission, her repeated CD4
+ cell count was 11% or 51 cells/mm
3 and her plasma HIV-RNA
level was < 50 copies/mL. Her skin biopsy showed necrotizing histiocytic granuloma formation with neutrophilic
infiltration in the upper and reticular dermis. Tissue sections stained with hematoxylin and eosin (H&E), periodic
acid-Schiff (PAS), and Grocott methenamine silver (GMS) stain revealed numerous intracellular and extracellular,
round to oval, elongated, thin-walled yeast cells with central septation. The hemoculture, bone marrow culture,
and skin culture revealed no growth of fungus or bacteria. Our patient responded well to intravenous
amphotericin B followed by oral itraconazole. She fully recovered after 4-month antifungal treatment without
evidence of recurrence of disease.
Conclusions: IRIS from P. marneffei in HIV-infected people is rare. Appropriate recognition and properly treatment
is important for a good prognosis.
Background
Penicillium marneffei is a dimorphic fungus which can
cause a fatal systemic mycosis in human immunodefi-
ciency virus (HIV)-infected patients. This organism is
endemic in tropical Asia, especially Thailand, northeast-
e r nI n d i a ,C h i n a ,H o n gK o n g ,V i e t n a m ,a n dT a i w a n
[1-6]. Disseminated P. marneffei infection is one of the
most common HIV-related opportunistic infections in
northern Thailand [5]. The typical manifestations of P.
marneffei infection in HIV-infected individuals include
fever, anemia, weight loss, skin lesions, generalized lym-
phadenopathy, and hepatomegaly [5,7]. The primary
treatment with amphotericin B and itraconazole and
secondary prophylaxis with itraconazole are very effec-
tive regimens [8]. Patients who do not receive timely
and appropriate antifungal treatment have poor out-
comes [5]. Immune reconstitution inflammatory syn-
drome (IRIS) is a complication related to antiretroviral
therapy (ART)-induced immune restoration. IRIS mani-
fests as a paradoxical exacerbation of previously treated
opportunistic infections (paradoxical or worsening IRIS)
or as an unmasking of subclinical, untreated infections
(unmasking IRIS) [9-12]. It is a consequence of exagger-
ated activation of the immuner e s p o n s ea g a i n s ti n f e c -
tious organisms [13,14]. In this report, we present a case
of HIV-infected child with IRIS from disseminated
P. marneffei infection.
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A 14-year-old Thai girl presented at a provincial hospi-
tal with fever, oral ulcers, disseminated papular lesions
and multiple joint pain for 4 weeks. Twelve weeks
before this admission, she was diagnosed as a case of
perinatal HIV infection after presenting with dissemi-
nated herpes zoster infection and Pneumocystis jirovecii
pneumonia (PJP). At that time, her CD4
+ cell count was
7.2% or 39 cells/mm
3.P l a s m aH I V - R N Al e v e lw a sn o t
obtained. She was started on GPOvirS30
® (a fixed drug
combination of stavudine 30 mg, lamivudine 150 mg
and nevirapine 200 mg) 1 tablet twice daily and PJP pro-
phylaxis with trimethoprim-sulfamethoxazole. Eight
weeks after starting ART she developed fever, multiple
oral ulcers, disseminated papular lesions over the face,
body, and extremities, and severe pain in many joints.
The symptoms did not respond to many kinds of oral
antibiotics and she was referred to Chiang Mai Univer-
sity (CMU) Hospital.
Upon admission to CMU Hospital, the physical exam-
ination revealed high-grade fever. Multiple painful ulcer-
ated lesions were found on the lip and oral mucosa.
Generalized non-pruritic erythrematous papules and
nodules with central umbilication were found over the
face, body, and extremities (Figure 1). Marked swelling,
warmth, and tenderness of many joints, including right
shoulder, wrist, metacarpophalangeal, knee, and ankle
joints were also noticed. Neither lymphadenopathy nor
hepatosplenomegaly were found. Her laboratory results
are shown in Table 1. CD4
+ cell count was 11% or 51
cells/mm
3. Plasma HIV-RNA level was < 50 copies/mL.
Chest roentgenogram was normal. Roentgenograms of
both wrists and ankles showed multiple round radiolu-
cent defects of the bones (Figure 2). Skin biopsy showed
necrotizing histiocytic granuloma formation with
neutrophilic infiltration in the upper and reticular der-
mis. Tissue sections from skin biopsy stained with
hematoxylin and eosin (H&E), periodic acid-Schiff
(PAS), and Grocott methenamine silver (GMS) stain
revealed numerous intracellular and extracellular, round
to oval, elongated, thin-walled yeast cells with central
septation (Figure 3). No organism was observed in the
bone marrow aspirate specimen. The hemoculture, bone
marrow culture, and skin culture revealed no evidence
of P. marneffei or other fungus. Blood was also sent for
mycobacterial culture with negative results. Serum cryp-
tococcal antigen was negative. The diagnosis of dissemi-
nated P. marneffei infection from unmasking IRIS was
made.
The patient was treated with intravenous amphotericin
B at a dosage of 0.7 mg/kg for 2 weeks along with para-
cetamol and ibuprofen, followed by oral itraconazole at
a dosage of 5 mg/kg twice daily orally. She responded
well to treatment. Her fever, skin lesions, and joints
pain gradually resolved. She was discharged with a plan
to complete a 10-week course of oral itraconazole ther-
apy followed by the maintenance therapy with oral itra-
conazole at a reduced dosage of 5 mg/kg daily. Her skin
lesions and joints pain resolved after 4 weeks of antifun-
gal treatment, and itraconazole was discontinued after 4
months of maintenance treatment. After 1 year of ther-
apy, she had gained 4 kg weight without recurrence of
P. marneffei infection. Her repeated CD4
+ cell count
had risen to 21.1% or 269 cells/mm
3. Her plasma HIV
RNA level was undetectable (< 50 copies/mL).
Conclusions
We reported a case of HIV-infected child who devel-
oped an unmasking IRIS caused by disseminated P.
marneffei infection 8 weeks after ART initiation. After
treatment with antifungal therapy, amphotericin B
Figure 1 Cutaneous lesions initially presented as small
papules, enlarged to larger papules with central necrotic
umbilications. They were predominantly found on the face and
extremities.
Table 1 Laboratory results on the day of admission
Laboratory investigations Results Normal value
Hemoglobin (g/dL) 8.0 10.0-15.0
Hematocrit (%) 23.9 36.0-45.0
White blood count (×10
9/L) 7.6 5-10
Absolute neutrophil count 5.9 2.0-8.0
Absolute lymphocyte count 0.5 0.7-4.4
Platelet (×10
9/L) 498 100-400
SGOT (U/L) 21 < 35
SGPT (U/L) 10 < 41
LDH (U/L) 161 120-450
ESR (mm/hr) > 140 0-10
CRP (mg/L) 80.7 0-5.0
Note: SGOT indicates Serum glutamic oxaloacetic transaminase; SGPT, Serum
glutamic pyruvic transaminase; LDH, Lactate dehydrogenase; ESR, Erythrocyte
sedimentation rate; CRP, C-reactive protein
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evidence of recurrence.
IRIS is a manifestation of vigorous immune recovery
which usually occurs within a few weeks to months
after potent ART initiation in advanced stage HIV-
infected patients. This inflammatory reaction is directed
against pathogens causing latent or subclinical infection.
The majority of patients present with unusual manifes-
tations of opportunistic infections, most often while the
number of CD4
+ cell count is increasing and/or the
plasma HIV RNA level is decreasing [11,12,15,16]. This
syndrome can be severe, and results in significant mor-
bidity and occasional mortality. The information about
incidence and spectrum of IRIS in HIV-infected children
was limited. Puthanakit et al. reported an incidence of
19% of IRIS in advanced stage Thai HIV-infected chil-
dren with the median onset of 4 weeks (range, 2-31)
after ART commencement. The three major causative
pathogens were mycobacterial spp.( 4 3 . 8 % ) ,b o t hMyco-
bacterium tuberculosis (TB) and non-tuberculous myco-
bacterium, varicella zoster virus (VZV) (21.9%), and
herpes simplex virus (HSV) (21.9%) [17]. Recently,
Smith et al. reported an incidence of 21% of IRIS in
South African HIV-infected children at a median of 16
days (range, 7-115 days) post-ART initiation. Bacillus
Calmette-Guérin reaction (71%) and TB (35.3%) were
the most common conditions in their children [18].
Similarly, Wang et al. reported an incidence of 20% of
IRIS (19.8 events per 100 person years) in HIV-infected
children in Peru with 6.6 weeks (range, 2-32) median
Figure 2 Radiologic evidences of osteolytic lesions of the extremities. a. Multiple osteolytic lesions are noted along the metaphyseal line of
the 2nd to 4th metacarpophalangeal joints (arrow) with pericarticular osteopenia of the wrist and metacarpophalangeal joints. Large osteolytic
lesions are also noted at right distal radius and ulnar (arrows). No widening of both wrist joint spaces. Sharp bony cortex of both radius and
ulnar. b. Multiple osteolytic lesions are noted at right calcaneous (arrow). No widening of both ankle joint spaces. Sharp bony cortex of both
tibia and fibula.
Figure 3 Photomicrograph of Penicillium marneffei (courtesy of Kornkanok Sukapan) in the skin lesion section stained with Grocott
Methenamine Silver. Numerous intracellular and extracellular, round to oval, elongated, thin-walled yeast-like organisms. The characteristic
transverse septum (arrows) within the yeast cell is seen. Magnification, × 1000.
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infection (33.3%), HSV labialis (33.3%), and TB infection
(22.2%) [19].
Our patient developed symptoms 8 weeks after the
initiation of ART, which is a common period for IRIS
development. They included fever, multiple painful oral
ulcers, disseminated umbilicated papular skin lesions
over the face, body and extremities, and multiple swol-
len, warm, and tender joints which are typical clinical
presentations of disseminated P. marneffei infection. Tis-
sue sections of the skin biopsy stained with H&E, PAS,
and GMS revealed numerous yeast cells of P. marneffei,
b u tc u l t u r ed i dn o ty i e l dt h eo r g a n i s mT h e s es i g n sa n d
symptoms, especially prominent inflammatory articular
manifestations, and an excessive inflammation reaction
in histopathology of the skin biopsyspecimen demon-
strated vigorous immune recovery which acted on unvi-
able P. marneffei antigens. Improvement of her immune
response was also evidenced by her rising CD4
+ cell
count and undetectable plasma HIV RNA level. The
improved immune response had unmasked a previously
quiescent P. marneffei infection causing the patient’s
symptoms.
P. marneffei is an important causative organism of
opportunistic infection in immunocompromised people,
particularly HIV-infected persons who live in or travel
to Southeast Asia [4-7,20]. By reviewing the English
medical literature, P. marneffei had been reported as a
causative organism of IRIS in only 4 HIV-infected
patients. The first case was reported in 2007 from India
[21]. Since then, there have been 2 additional cases
reported from the Indian subcontinent [22,23], and 1
case from United Kingdom who had traveled to Thai-
land [24]. Case histories and the characteristics of these
4 cases are summarized in Table 2. All patients lived in
or traveled to an endemic area of P. marneffei. Similar
with our patient, all except one case (case 1) had evi-
dences of immune recovery during IRIS presentation
which occurred within 2-4 weeks after ART initiation.
Both kinds of IRIS presentations were reported, 3 as
unmasking, and 1 as paradoxical types. All except 1
patient (case 1) had generalized skin and/or mucocuta-
neous lesions which are the common clinical character-
istics of P. marneffei infection. The common presenting
symptoms were generalized skin and/or mucocutaneous
lesions, pyrexia, lymphadenopathy, hepatomegaly and
splenomegaly. Our patient also had osteoarticular invol-
vement by clinical and/or radiological findings, similar
to case 2 in Table 2. The osteomyelitis was seen in mul-
tiple including flat bones, long bones of the extremities
and the small bones of hands and feet. The arthritis
could involve both large peripheral joints and small
joints of the fingers [20,25-27]. These findings were
similar to those observed in tuberculosis and systemic
mycoses other than penicilliosis [28].
Diagnosis of infection by P. marneffei is usually made
by identifying the fungus in clinical specimens by micro-
scopy and culture. In addition, P. marneffei can be seen
in histopathological sections stained with H&E, GMS, or
PAS stain, which typically appears as unicellular round
to oval yeast cells with transverse septum in macrophage
or histiocyte [29]. This finding is unique to infection
with P. marneffei. All 4 previously reported cases had
evidences of the fungus in the clinical specimens,
including blood, skin biopsies, and lymph node biopsies
and culture [21-24]. However, in our reported case, we
found the evidences of organism in histopathological
sections with special stains but could not identify fungus
by culture of the clinical specimens. This might be due
to the fact that the organism was already killed by the
immune system of the patient.
Treatment of disseminated P. marneffei infection is well
described [30]. Intravenous amphotericin B for 2 weeks
followed by oral itraconazole for 10 weeks is recom-
mended. Although itraconazole maintenance treatment
was shown to prevent relapse of penicilliosis when the
patients had CD4 cell count of 100 cells/μl or greater for
at least 6 months after HAART [31], our patient who
unintentionally discontinued maintenance treatment after
4-month therapy without knowing the CD4 cell count
did not have relapse. Details of treatments and outcomes
were available in 3 of 4 previously reported cases (Table
2). Two cases (case 1, 4) were treated with intravenous
amphotericin B for 2 weeks, followed by oral itraconazole
for 10 weeks. The other case (case 3) received single dose
of intravenous amphotericin B because the patient
refused to stay in the hospital. Therefore, he was treated
by only itraconazole orally for 8 weeks. All 3 cases were
continued on maintenance treatment with oral itracona-
zole along with the ART. Their symptoms improved
markedly after 2-10 months of the therapy.
In summary, IRIS is not a rare condition, especially in
the ART era. IRIS caused by P. marneffei infection will
be increasingly recognized in the endemic area of the
fungus. It requires appropriate recognition and proper
treatment. The clinicians’ awareness is crucial to ensure
a good prognosis.
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Page 4 of 6Table 2 Immune reconstitution inflammatory syndrome with disseminated Penicillium marneffei infection in HIV-infected patients: Literature review
Case Country
reported
year
Age
(yr)
Sex Status before ART commencement Type
of
ART
Type of
IRIS
Time
to
IRIS
onse
Status during IRIS presentation Method
for
diagnosis
Treatments Outcomes
Clinical symptoms CD4
cell
count
(cells/
mm
3)
Viral
load
(copies/
mL)
Clinical symptoms CD4
cell
count
(cells/
mm
3)
Viral
load
(copies/
mL)
1 India
24,
2007
35 M fever, loss of weight
and appetite,
hepatosplenomegaly,
herpes genitalis
4 NA d4T,
3TC,
NVP
unmasking 4
weeks
afebrile, pallor, mild
icterus, cervical and
axillary
lymphadenopathy,
hepatosplenomegaly
NA NA axillary LN
biopsy-
positive,
LN culture-
positive
blood
culture
-positive,
AmphoB 0.6 MKD
for 14 days,
followed by
itraconazole 400
mg/d for 10 wks,
then MT with 200
mg/d
At 10 mo; 20
kg weight
gain,
decrease size
of LN, liver,
spleen, CD4
= 224 cells/
mm
3
2 India
25,
2009
12 M fever, cough, weight
loss, diarrhea,
generalized papular
umbilicated lesion,
oral and esophageal
candidiasis
11 NA d4T,
3TC,
EFV
paradoxical 4
weeks
fever, severe arthritis,
exacerbration of skin
lesions, generalised
lymphadenopathy
172
(wk 4)
NA blood
culture-
positive
NA NA
3 India
26,
2010
28 M fever, cough, loss of
weight, diarrhea, oral
candidiasis
47 NA d4T,
3TC,
NVP
unmasking 2
weeks
multiple erythrematous,
scaly, papules and
nodules with central
necrosis on face
extremities, scortum
160
(wk 2)
NA skin
biopsy-
positive,
skin
culture-
positive,
blood
culture-
negative
AmphoB 0.6 MKD
only 1 dose, then
itraconazole 400
mg/d for 2 mo,
then MT with 200
mg/d
At 2 mo; 14
kg weight
gain, skin
lesions
disappear
4U K
(traveled
to
Thailand)
27, 2010
39 M fever, loss of weight
and appetite, PJP,
molluscum
contangiosum on
face
72 38000000 TDF,
FTC,
EFV
unmasking 4
weeks
multiple facial lesions,
disseminated non-
pruritic nodules, no
hepatosplenomegaly
273
(wk 8)
3 log
drop
(wk 4)
pus
culture-
positive
AmphoB 0.6 MKD
for 14 days,
followed by
itraconazole 600
mg/d for 10 wks,
then MT with 200
mg/d
At 2 mo; skin
lesions
regress At 28
mo; CD4 =
375 cells/
mm
3,V L<5 0
copies/mL
5 Thailand,
2011
(Ours)
14 F fever, loss of weight
and appetite, PJP,
herpes zoster on
trunk
39 NA d4T,
3TC,
NVP
unmasking 8
weeks
fever, severe
osteoarthritis,
disseminated non-
pruritic papules and
nodules with central
necrosis, oral ulcer, no
lymphadenopathy, no
hepatosplenomegaly
51
(wk 14)
<5 0
(wk 14)
skin
biopsy-
positive,
skin
culture-
negative,
blood
culture-
negative
AmphoB 0.7 MKD
for 14 days then
Itraconazole 5 MK
twice daily for 10
weeks, then MT
with 5 MKD for 4
months
At 12 mo; 4
kg weight
gain, CD4 =
269 cells/
mm
3,V L<5 0
copies/mL
Note: M indicates male; d4T, stavudine; 3TC, lamivudine; TDF, tenofovir; FTC, emtricitabine, EFV, efavirenz; NVP, nevirapine; LN, lymph node; AmphoB, Amphotericin B deoxycholate; MKD, mg/kg/day; MT,
maintenance; VL, plasma HIV RNA level; NA, not available
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